Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parabilis MedicinesPBLS -4.66%10 OCF Yield % is -3.23 as of Jul. 25, 2026. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Parabilis Medicines ranks better than 65.67% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Parabilis Medicines OCF Yield % Related Terms
Parabilis Medicines OCF Yield % Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines OCF Yield % Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
OCF Yield %
0.00
0.00
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
OCF Yield %
0.00
0.00
PBLS vs IDYA, ELVN, BEAM: OCF Yield % Comparison
For the Biotechnology subindustry, Parabilis Medicines's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a OCF Yield % of -3.23 as of Jul. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #484 out of 1410 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Parabilis Medicines' OCF Yield % too high?
Parabilis Medicines' current OCF Yield % is -3.23. Based on the distribution chart, Parabilis Medicines ranks #484 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' OCF Yield % compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #484 out of 1410 companies for OCF Yield %. This puts Parabilis Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current OCF Yield % is -3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current OCF Yield % of -3.23. The current OCF Yield % is -3.23. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current OCF Yield % is -3.23 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
